Trial Profile
A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2015
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Alimera Sciences
- 28 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 16 Sep 2014 New trial record